Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL733345 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2 | |
| SCHEMBL11154269 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2 | |
| SCHEMBL852296 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2 | |
| SCHEMBL5908153 | 0.89 | SRD5A2 (0.80) | SRD5A1SRD5A2 | |
| SCHEMBL7000399 | 0.89 | SRD5A2 (0.80) | SRD5A1SRD5A2 | |
| SCHEMBL11141410 | 0.88 | SRD5A1 (0.79) | SRD5A1SRD5A2 | |
| SCHEMBL11141415 | 0.88 | SRD5A1 (0.79) | SRD5A1SRD5A2 | |
| SCHEMBL11139621 | 0.87 | SRD5A1 (0.76) | SRD5A1SRD5A2 | |
| SCHEMBL11139619 | 0.87 | SRD5A1 (0.76) | SRD5A1SRD5A2 | |
| SCHEMBL9022351 | 0.85 | SRD5A1 (0.74) | SRD5A1SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | SRD5A1 231/4885SRD5A2 356/4885 |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, EIF2AK2, RNASE1 | SRD5A1 518/4885SRD5A2 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.